ĿŚ.



https:/doi.org/10.1093/ckj/sfad218 Advance Access Publication Date: 4 September 2023 Original Article

# ORIGINAL ARTICLE

# Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation

Cédric Villain <sup>[]</sup>, Natalie Ebert <sup>[]</sup>, Tim Bothe <sup>[]</sup>, Muhammad Barghouth <sup>[]</sup>, Anna Pöhlmann <sup>[]</sup>, Anne-Katrin Fietz <sup>[]</sup>, Antonios Douros <sup>[]</sup>, Nina Mielke <sup>[]</sup> and Elke Schaeffner <sup>[]</sup>

<sup>1</sup>Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Public Health, Berlin, Germany, <sup>2</sup>Normandie Univ UNICAEN, INSERM U1075 COMETE, service de Gériatrie, CHU de Caen, Caen, France, <sup>3</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany, <sup>4</sup>Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada and <sup>5</sup>Institute of Clinical Pharmacology and Toxicology, Charité -Universitätsmedizin Berlin, Berlin, Germany

Correspondence to: Cédric Villain; E-mail: villain-c@chu-caen.fr

# ABSTRACT

**Background.** The Cockcroft–Gault equation ( $CrCl_{C-G}$ ) is recommended for dose adjustment of direct oral anticoagulant drugs (DOACs) to kidney function. We aimed to assess whether defining DOAC dose appropriateness according to various kidney function estimators changed the associations between dose appropriateness and adverse events in older adults with atrial fibrillation (AF).

**Methods.** Participants of the Berlin Initiative Study with AF and treated with DOACs were included. We investigated  $CrCl_{C-G}$  and estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium equations based on creatinine and/or cystatin C. Marginal structural Cox models yielded confounder-adjusted hazard ratios for the risk of mortality, thromboembolism and bleeding associated with dose status.

**Results.** A total of 224 patients were included in the analysis (median age 87 years). Using CrCl<sub>C-G</sub>, 154 (69%) had an appropriate dose of DOACs, 52 (23%) were underdosed and 18 (8%) were overdosed. During a 39-month median follow-up period, 109 (14.9/100 person-years) participants died, 25 (3.6/100 person-years) experienced thromboembolism and 60 (9.8/100 person-years) experienced bleeding. Dose status was not associated with mortality and thromboembolism, independent of the equation. Underdose status was associated with a lower risk of bleeding with all the equations compared with the appropriate dose group. In participants with discrepancies in dose status using CrCl<sub>C-G</sub> and eGFR equations, the occurrence of endpoints did not differ between participants having an appropriate dose using CrCl<sub>C-G</sub> or eGFR.

**Conclusion.** In older adults with AF, the association of DOAC dose status with adverse events did not differ when using  $CrCl_{C-G}$  or eGFR. Our results suggest that eGFR equations are not inferior to  $CrCl_{C-G}$  within this context.

Received: 7.6.2023; Editorial decision: 25.7.2023

<sup>©</sup> The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

# **GRAPHICAL ABSTRACT**



Keywords: atrial fibrillation, creatinine clearance, glomerular filtration rate, older adults, oral anticoagulant drug

# INTRODUCTION

Direct oral anticoagulants (DOACs) are recommended as firstline therapy in non-valvular atrial fibrillation (NVAF) [1]. Dose adjustment is necessary when kidney function is reduced. Guidelines of the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recommend the use of creatinine clearance estimated by the Cockcroft–Gault equation (CrCl<sub>C-G</sub>) for this drug class [2, 3]. The CrCl<sub>C-G</sub> was used for drug dose adjustment for kidney function in the pivotal randomized controlled trials on DOACs in NVAF patients [4]. Several studies showed that the use of inappropriately dosed DOACs was associated with an increased risk of death [5–8], bleeding [9–12] and thromboembolism [10–12].

Due to the limited performance of the CrCl<sub>C-G</sub> in determining the estimated glomerular filtration rate (eGFR), healthcare regulatory agencies recently proposed the use of eGFR equations for dose adjustment of other drug classes [13, 14]. In clinical routine, eGFR is based on serum creatinine, but combining serum creatinine with cystatin C leads to more accurate eGFRs [15, 16]. Recent studies found that patients having discrepancies in DOAC dose status according to the equations used (i.e. appropriate with the CrCl<sub>C-G</sub> and inappropriate with the eGFR equation, or vice versa) were exposed to higher risks of thromboembolism and bleeding than patients without discrepancies [17, 18]. One study in dabigatran users found that underdose determined using the CrCl<sub>C-G</sub> or Chronic Kidney Disease Epidemiology Collaboration eGFR (eGFR<sub>CKD-EPI</sub>) equation was associated with a higher risk of thromboembolism as compared with appropriate dose, but overdose was associated with a higher risk of bleeding only when using the  $CrCl_{C-G}$  [12]. However, to the best of our knowledge, this has not been studied in patients treated with other DOACs or using eGFR equations that include cystatin C.

Dose adjustment of DOACs is especially relevant in older adults, where the  $CrCl_{C-G}$  has sometimes been shown to have poor performance [19]. The prevalence of NVAF and chronic kidney disease (CKD) dramatically increases in older age [20, 21]. Older adults are more prone to adverse drug reactions and oral anticoagulant drugs are among the most represented drugs in iatrogenic events [22]. Finally, an inappropriate dose of DOACs is frequent in older ages [5–9, 23], as are discrepancies in dose status of DOACs depending on kidney function estimators [12, 17, 24].

Using data from the Berlin Initiative Study (BIS), we aimed to assess whether defining dose appropriateness of DOACs according to various kidney function estimators (with or without cystatin C) modified the association between dose appropriateness and mortality, thromboembolism and bleeding in older adults with NVAF. We hypothesized that determination of the DOAC dose using eGFR equations would not be inferior to the use of the  $CrCl_{C-G}$  in terms of association with endpoints.

#### MATERIALS AND METHODS

#### Study design and population

The BIS is a population-based prospective cohort study in Berlin, Germany, to evaluate kidney function in individuals  $\geq$ 70 years of age. Criteria for study inclusion were age  $\geq$ 70 years and membership at the statutory health insurance company Allgemeine Ortskrankenkasse (AOK) Nordost. Patients on dialysis, with kidney transplantation or with the highest level of care at baseline were excluded. All participants gave written informed consent before enrolment in the study. The study protocol was approved by the local ethics committee (EA2/009/08). Participants were followed up biennially until 2019. Detailed information on the design of the BIS is available in the Supplementary Methods and has been described elsewhere [25, 26].

In this analysis, we included BIS participants with a history of NVAF or flutter who were treated with DOACs on at least one follow-up visit and had a CHA2DS2-VASc >2 in men and >3 in women [1]. History of NVAF and flutter were defined using the German modification of the 10th revision of the International Classification of Diseases (ICD-10-GM) codes from the claims data (details in Supplementary Table 1). Participants were considered as having atrial fibrillation, flutter or valvular heart disease if they had at least one hospital or at least two ambulatory ICD-10-GM codes for the respective diagnosis before a followup visit. Participants were counted as being treated with DOACs if they had at least one dispensed prescription for apixaban, dabigatran, edoxaban or rivaroxaban in the 4 months before the study visit. We chose a 4-month period for its clinical relevance because a shorter period would have led to the exclusion of participants actually taking DOACs but who did not renew their prescription during that period, and a longer period would have led to the inclusion of participants who could have stopped taking DOACs before the follow-up visit.

Baseline data correspond to the first study visit where inclusion criteria were met. Participants were censored if they stopped taking DOACs between two follow-up visits (i.e. no prescription for DOACs in the 4-month period before the latter visit) and were then censored at the date of the latter visit, they died during follow-up or experienced a secondary endpoint or the end of the observation period (31/12/2021), whatever occurred first.

The primary endpoint was all-cause mortality. Death status was actively searched for biannually using both AOK data as well as official death certificates for all BIS participants. The secondary endpoints were hospitalization due to bleeding or thromboembolism, defined as stroke or transient ischaemic attack or systemic embolism, using at least one ICD-10-GM code based on hospital claims data (Supplementary Table 1).

#### Exposures

The type of DOAC and dose status were updated at each followup visit. The last prescription before the study visit was used to define DOAC dose. Appropriateness of the DOAC dose was assessed using EMA guidelines for dose adjustment of DOACs (details in Supplementary Table 2) [4]. Any participant with a higher dose than recommended according to the patient's characteristics or a contraindication to the considered DOAC use due to low kidney function was defined as overdosed. Any participant with a lower dose than expected for the respective DOAC according to the patient's characteristics was defined as underdosed. All others were defined as appropriately dosed. Drug dose status was assessed using the  $CrCl_{C-G}[2]$ , eGFR<sub>CKD-EPI</sub> [16] and the European Kidney Function Consortium (eGFR<sub>EKFC</sub>) [15] equations (details in Supplementary Methods). For the two latter equations, we considered their versions based on serum creatinine (eGFR<sub>CKD-EPIcr</sub>, eGFR<sub>EKFCcr</sub>), serum cystatin C (eGFR<sub>CKD-EPIcys</sub>, eGFR<sub>EKFCcys</sub> in its sex-specific version) and both biomarkers (eGFR<sub>CKD-EPIcr</sub>, eGFR<sub>EKFCcr</sub>). For drug dose adjustment, an eGFR expressed in ml/min is recommended by calculating the patient's individual body surface area (BSA) [13, 14]. The eGFR<sub>CKD-EPI</sub> and eGFR<sub>EKFC</sub> equations were thus expressed in ml/min after taking the estimated BSA using the Dubois equation into account. Kidney function and BSA were updated at each follow-up visit. Detailed information on other variables is available in the Supplementary Methods.

#### Statistical analyses

Participants' characteristics were described using absolute and relative frequencies for categorical variables and mean  $\pm$  standard deviation (SD) or median [1st–3rd quartiles (IQR)] for continuous variables, depending on the distribution. The association between the participants' characteristics and dose status according to the CrCl<sub>C-G</sub> was assessed using univariable multinomial logistic regression models.

The association between endpoints and dose status was assessed using marginal structural Cox models in order to account for changes in dose status over time [27, 28]. These models were chosen because they better control for the effects of time-varying confounders that are affected by prior treatment and allow for control for informative censoring compared with multivariate time-varying Cox models [27]. Detailed information on these models is available in the Supplementary Methods. Subgroup analyses were performed in participants taking apixaban or rivaroxaban and those with an  $eGFR_{CKD-EPIcr}$ <60 ml/min/1.73 m<sup>2</sup>, according to the current definition of CKD stages 3-5. Due to the small number of participants, we were unable to perform subgroup analyses in dabigatran and edoxaban users. Due to the low incidence rate of thromboembolism, we did no further subgroup analyses. In patients with discrepant dose status using the  $\mbox{CrCl}_{C\text{-}G}$  and eGFR equations, we compared the occurrence of endpoints using the equation for which the dose status was considered appropriate. We used univariable logistic regression for this last analysis due to the small sample size.

Finally, we assessed the discrepancy in dose status according to indexed (i.e. expressed in ml/min/1.73 m<sup>2</sup>) and de-indexed (i.e. expressed in ml/min) eGFR and investigated if the dose status based on the indexed eGFR was associated with the occurrence of the study endpoints.

Missing values were taken into account by computing multiple imputations using multiple chained equations, assuming that data were missing at random [29]. For each missing value, 20 imputations were computed, leading to 20 different databases. The results of the 20 databases were pooled according to Rubin's rules [30]. Statistical analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria). Effect estimates are presented alongside 95% confidence intervals (CIs). All analyses were performed in an exploratory manner and adjustment for multiple testing was not performed to avoid suppression of potential signals.

# RESULTS

#### Study population

Among the 2069 participants of the BIS, 224 were included in the present analysis (flow diagram in Supplementary Fig.1). At baseline, the median age was 87 years and 115 (51%) participants were female. A total of 99 (44%) participants were treated with rivaroxaban, 86 (38%) with apixaban, 21 (9%) with edoxaban and 18 (8%) with dabigatran. Detailed characteristics of the study population are presented in Table 1.

#### Dose status according to patients' characteristics, drugs and kidney function estimators

When using the CrCl<sub>C-G</sub>, 154 (69%) had appropriate dose status, 52 (23%) were underdosed and 18 (8%) were overdosed at baseline. Univariate associations between patients' characteristics and dose status are shown in Table 2 . Compared with patients with an appropriate dose, underdosed patients were significantly older and overdosed patients were more likely to be female, to have lower HAS-BLED scores, Charlson Comorbidity Index (CCI) and body mass index (BMI) and were less likely to have coronary artery disease. Dose status according to kidney function estimators and drugs are shown in Fig. 1. Appropriate dose status varied from 100% in dabigatran users to 58% in apixaban users (Fig. 1B). Underdose and overdose status were more frequently found in apixaban users (38%) and edoxaban users (19%), respectively. Proportions of patients with an appropriate dose ranged from 63% with the  $eGFR_{CKD-EPIcr}$  to 69% with the CrCl<sub>C-G</sub> (Fig. 1A). Discrepancies in dose status when using the  $CrCl_{C\text{-}G}$  or the other equations ranged from 7% (for  $eGFR_{EKFCcr}$ and eGFR<sub>EKFCcr-cys</sub>) to 13% (for eGFR<sub>CKD-EPIcys</sub> and eGFR<sub>EKFCcys</sub>).

#### Association of dose status and endpoints

During a median follow-up of 39 months (IQR 28–58), of 224 participants, 109 (14.9/100 person-years) died, 60 (9.8/100 personyears) were hospitalized with a bleeding diagnosis and 25 (3.6/100 person-years) were hospitalized with a thromboembolism diagnosis. Fig. 2 shows the association of the endpoints with dose status according to the studied equations. Using marginal structural Cox models, dose status was not associated with the occurrence of death and thromboembolism, independent of the equation. Underdose status was associated with a lower risk of bleeding compared with the appropriate dose group, whereas overdose status was not associated with bleeding, whatever the equation used.

#### Subgroup analyses

In apixaban users, dose status was not significantly associated with death or bleeding (Supplementary Table 3). In rivaroxaban users, underdose using the CrCl<sub>C-G</sub> and eGFR<sub>CKD-EPIcys</sub> was associated with a significantly higher risk of death. Underdose using the eGFR<sub>CKD-EPIcr</sub> was associated with a significantly lower risk of bleeding as compared with the appropriate dose group, whereas the other associations were not statistically significant (Supplementary Table 4). In participants with an eGFR<sub>CKD-EPIcr</sub> <60 ml/min/1.73 m<sup>2</sup>, underdose was associated with a lower risk of bleeding compared with the appropriate dose group, except when using the CrCl<sub>C-G</sub> (Supplementary Table 5).

In patients with discrepant dose status using the  $CrCl_{C-G}$  and eGFR equations, we compared the occurrence of endpoints using the equation for which the dose status was considered appropriate (Fig. 3). No significant difference in endpoint occurrence was

Table 1: Characteristics of the study population at baseline (N = 224).

Variable	Value	Missing values n (%)ª
Sociodemographic variables		
Age (years), median (IQR)	87 (81–91)	
Female, n (%)	115 (51)	
Non-smoker, n (%)	114 (51)	3 (1)
Former smoker, n (%)	102 (45)	
Current smoker, n (%)	8 (4)	
Daily alcohol consumption, n (%)	14 (6)	2 (1)
Comorbidities, n (%)		
Hypertension	218 (97)	
Diabetes	69 (31)	13 (6)
Heart failure	173 (77)	
Coronary artery disease	167 (75)	
Peripheral artery disease	153 (68)	
Prior stroke or transient ischaemic attack	64 (29)	
Prior systemic embolism	14 (6)	
Prior bleeding event	157 (70)	
Bleeding predisposition	115 (51)	
Dementia	62 (28)	
Liver disease	57 (25)	
Cancer	14 (6)	2 (1)
CCI, median (IQR)	7 (5–10)	
CHA2DS2-VASc, median (IQR)	6 (5–7)	
HAS-BLED score, median (IQR)	3 (3–4)	
Nutritional and functional status Frailty status, n (%) Non-frail, n (%) Pre-frail, n (%) Frail, n (%) History of falls, n (%) BMI (kg/m <sup>2</sup> ), median (IQR)	43 (19) 87 (39) 94 (42) 45 (20) 27 (25–30)	79 (35) 5 (2)
BSA (m <sup>2</sup> ), median $\pm$ SD	$1.82\pm0.18$	5 (2)
Kidney function estimators, median (IQR)		
CrCl <sub>C-G</sub> (ml/min)	45 (36–60)	20 (9)
eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> )	56 (41–68)	19 (8)
eGFR <sub>CKD-EPIcys</sub> (ml/min/1.73 m <sup>2</sup> )	44 (32–57)	20 (9)
eGFR <sub>CKD-EPIcr-cys</sub> (ml/min/1.73 m <sup>2</sup> )	48 (36–62)	20 (9)
eGFR <sub>EKFCcr</sub> (ml/min/1.73 m <sup>2</sup> )	50 (37–60)	19 (8)
eGFR <sub>EKFCcys</sub> (ml/min/1.73 m <sup>2</sup> )	46 (35–59)	20 (9)
eGFR <sub>EKFCcr-cys</sub> (ml/min/1.73 m <sup>2</sup> )	47 (36–59)	20 (9)
Medication, n (%)		
Apixaban	86 (38)	
Dabigatran	18 (8)	
Edoxaban	21 (9)	
Rivaroxaban	99 (44)	
Antiplatelet agent	22 (10)	
NSAIDs	32 (14)	
DOAC prescription duration (years), median (IQR)	0.8 (0.3–1.4)	
Total number of drugs per patient, median (IOR)	7 (5–9)	

<sup>a</sup>The variables without any mention did not have missing values.

 $\rm CrCl_{C-G}$ : creatinine clearance estimated by the Cockcroft-Gault equation; eGFR<sub>CKD-EPI</sub> and eGFR<sub>EKFC</sub>: glomerular filtration rate estimation using the Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium equations, based on serum creatinine ( $\sigma$ ) and/or serum cystatin (cys); DOAC: direct oral anticoagulant drug; NSAIDs: non-steroidal anti-inflammatory drugs.

Table 2: Association between dose status accordir	g to the Cockcroft–Gault equation and pa	atients' characteristics at baseline (N $=$ 224)	•
---	--	--	---

		Appropriate dose (Ref) ( $n = 154$ )	Under	rdose (n = 52)	Over	dose (n = 18)
Age (years), median (LQR)         87 (81–90)         87 (82–91)         1.06 (1.01–1.11)*         88 (81–92)         0.99 (0.92–1.05)*           Sex         Male         55         40         1         23         1           Fernale         45         60         1.46 (0.87–2.45)         77         2.56 (1.08–6.10)           No         3         2         1         0         1         Yes         0.58 (0.11–2.35)           Diabetes         97         98         1.18 (0.30–6.48)         100         0.58 (0.11–2.35)           No         70         63         1         79         1           Ne         70         63         1         79         1           No         23         13         1         28         1         48           Yes         76         77         1.44 (0.63–2.06)         52         0.41 (0.18–0.91)           Peripheral artery disease         76         77         1.42 (0.80–2.53)         63         0.65 (0.27–1.49)           No         24         23         1         48         1         1.22 (0.25–1.68)         10.0.55 (0.12–1.07)           Prior systemic embolism         71         68         1.22 (0.25–1.68) <td< th=""><th>Variable</th><th>Value<sup>a</sup></th><th>Value<sup>a</sup></th><th>OR (95% CI)<sup>b</sup></th><th>Value<sup>a</sup></th><th>OR (95% CI)<sup>b</sup></th></td<>	Variable	Value <sup>a</sup>	Value <sup>a</sup>	OR (95% CI) <sup>b</sup>	Value <sup>a</sup>	OR (95% CI) <sup>b</sup>
Sec         Solve 2.9         Sol	Age (years) median (IOR)	87 (81–90)	87 (82–91)	1 06 (1 01–1 11) <sup>c</sup>	88 (81–92)	0.99 (0.92–1.06)
Make         55         40         1         23         1           Permale         45         60         1.46 (0.87-245)         77         2.56 (1.08-61.0)           No         3         2         1         0         1           No         3         2         1         0         0.58 (0.11-2.95)           Diabetes	Sex	0, (01, 50)	0, (02 5 1)	100 (101 111)	00 (01 02)	0.000 (0.002 1.000)
Term le10101010Hypertension32101No32101Yes97981.18 (0.30-4.68)1000.58 (0.11-2.55)Diabetes70631791No70631791Yes30371.02 (0.58-1.30)210.70 (0.40-2.39)Heart fulue77871.83 (0.91-3.68)720.61 (0.26-1.44)Coronary attry disease76771.14 (0.63-2.06)520.41 (0.18-0.91)Peripheral attry disease711.42 (0.80-2.53)630.65 (0.29-1.46)Prof systemic embolism32291371No322913711.22 (0.42-39)Prof systemic embolism716818811No71681.79 (0.74-5.1)11.12 (0.62-2.47)11.12 (0.62-2.47)Prof systemic embolism73630.98 (0.56-1.71)681.02 (0.42-2.47)No75691.36 (0.77-2.46)150.39 (0.31-1.56)Level disposition72751701No72751701No72751701No72751701No72751701No72751701No	Male	55	40	1	23	1
Hypertension         1.5         6.7         1.10 (ab. 1.0)         7.5         1.00 (ab. 1.0)         7.5           No         3         2         1         0         1           No         30         37         1.00 (ab. 2.48)         1.00 (ab. 2.48)           Diabetes	Female	45	60	1 46 (0 87–2 45)	77	2 56 (1 08-6 10)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hypertension	15	00	1.10 (0.07 2.15)	,,,	2.50 (1.00 0.10)
No.         97         98         1.18 (0.30-4.68)         100         0.58 (0.11-2.95)           Dibbetes	No	3	2	1	0	1
Diabetes	Vec	97	98	1 18 (0 30-4 68)	100	0 58 (0 11_2 95)
No.         70         63         1         79         1           Yes         30         37         1.02 (0.58-1.80)         21         0.97 (0.40-2.39)           Heart failure	Diabetes	57	50	1.10 (0.50 1.00)	100	0.50 (0.11 2.55)
Tes30371.02 (0.58-1.80)210.97 (0.40-2.39)Heart failureNo23131281Yes77871.83 (0.91-3.68)720.61 (0.26-1.44)Coronary attery disease24231481Yes76771.14 (0.63-2.06)520.41 (0.18-0.91)Peripheral attery disease76771.14 (0.63-2.06)520.41 (0.18-0.91)Prior systemic embolism32291371Yes68711.42 (0.80-2.53)630.65 (0.29-1.46)Prior systemic embolism71681881Yes29320.97 (0.56-1.68)110.35 (0.12-1.07)Prior systemic embolism5921891No71630.98 (0.51-71)101.02 (0.42-47)No273712212No75691851Yes25311.38 (0.77-2.46)150.99 (0.31-1.56)Liver disease72751701No72751701Yes28251.12 (0.63-1.99)3037 (0.27-1.98)CIAZDSZ-VASC score, median (IQR)6 (5-7)6 (5-7)10100.46 (0.42-0.39)CIAZDSZ-VASC score, median (IQR)6 (5-7)6 (5-7)1010100.46 (0.42-0.39)CIAZDSZ-VASC scor	No	70	63	1	79	1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes	30	37	1 02 (0 58-1 80)	21	0 97 (0 40-2 39)
No         23         13         1         28         1           Yes         77         87         1.83 (0.91-3.68)         72         0.61 (0.26-1.44)           Coronary attery disease         76         77         1.14 (0.63-0.60)         52         0.41 (0.18-0.91)           Peripheral attery disease         76         77         1.14 (0.63-0.60)         52         0.41 (0.18-0.91)           Prior stoke or transient ischaemic attack         71         68         1         38         1           Yes         68         71         1.42 (0.80-2.51)         63         0.50 (0.29-1.46)           Prior stoke or transient ischaemic attack         71         68         1         88         1           Yes         29         32         0.97 (0.56-1.68)         11         0.35 (0.12-1.07)           Prior systemic embolism         73         63         0.98 (0.56-1.71)         68         1           No         77         63         0.98 (0.56-1.71)         68         1.02 (0.42-4.79)           Bleeding event         7         73         1         32         1           No         27         51         1         76         9         1           Ne	Heart failure	30	57	1.02 (0.50 1.00)	21	0.57 (0.10 2.55)
TesToToToToToToVes77871.83 (0.91-3.68)720.61 (0.26-1.44)Coronary artery disease771.14 (0.63-2.06)520.41 (0.18-0.91)Peripheral artery disease711.44 (0.63-2.06)520.41 (0.18-0.91)Prior stroke or transient ischaemic attack8711.40 (0.80-2.53)630.65 (0.29-1.46)Prior stroke or transient ischaemic attack71681881No716818811Yes29320.97 (0.56-1.68)110.35 (0.12-107)Prior stroke or transient ischaemic attack95921891No7581.79 (0.71-4.51)111.32 (0.28-6.13)Prior bleeding event77371221No27371221No27371321Yes5541.60 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No727517011Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CIADDS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.00 (0.84-1.05)510.98 (0.71-1.12)51-80No72751701111.40 (0.45-4.39)No727517011 <td>No</td> <td>23</td> <td>13</td> <td>1</td> <td>28</td> <td>1</td>	No	23	13	1	28	1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Vec	77	87	1 83 (0 91_3 68)	72	0 61 (0 26-1 44)
No24231481Yes76771.14 $(0.3206)$ 52 $0.41$ $(0.18-0.91)$ Peripheral artery disease871 $14$ $(0.3206)$ 52 $0.41$ $(0.18-0.91)$ Prior stroke or transient ischaemic attack871 $14$ $(0.80-2.53)$ $63$ $0.65$ $(0.29-1.46)$ Prior stroke or transient ischaemic attack71 $68$ 1 $88$ 1 $88$ $1$ No71681881 $33$ $(0.12-0.7)$ Prior systemic embolism95921 $89$ 1No95921 $89$ 1 $32$ $21$ Yes58 $1.79$ $0.71-4.51$ $113$ $20.28-6.13$ Prior bleeding event7363 $0.98$ $0.56-1.71$ $68$ $102$ $0.42-2.47$ Bleeding predisposition84616511No75691851 $93$ $0.37$ $0.22-4.91$ No727517011111Yes2825 $1.20$ $0.63-1.80^\circ$ $5.6-7$ $0.97$ $0.62-7.99$ $0.46$	Coronary artery disease	,,,	0/	1.05 (0.51 5.00)	72	0.01 (0.20 1.11)
TwoL1L2L3L3L4L6L4L6L7L7L6L7L7L6L7L7L7L6L7L7L7L7L6L7 <thl7< th="">L7L7L7L7L7<td>No</td><td>24</td><td>23</td><td>1</td><td>48</td><td>1</td></thl7<>	No	24	23	1	48	1
Inclusion	Ves	76	77	1 14 (0 63-2 06)	52	0 41 (0 18_0 91)
No32291371Yes68711.42 (0.80-2.53)630.65 (0.29-1.46)Prior stroke or transient ischaemic attack71681881No71681881Yes29320.97 (0.56-1.68)110.35 (0.12-1.07)Prior systemic embolism $32$ $32$ $0.97 (0.56-1.68)$ 11 $0.35 (0.12-1.07)$ Prior Systemic embolism $32$ $32$ $0.97 (0.56-1.68)$ 11 $1.32 (0.28-6.13)$ Prior bleeding event $31$ $32$ $1$ $32$ $1$ No2737 $1$ $32$ $1$ Yes2554 $1.66 (0.87-2.45)$ $35$ $0.69 (0.31-1.56)$ Eleding predisposition $31$ $38 (0.72-2.46)$ $35$ $6.9 (0.31-1.56)$ Liver disease $75$ $69$ $1$ $85$ $1$ No7275 $1$ $70$ $1$ Yes28 $25$ $1.12 (0.63-1.99)$ $30$ $0.73 (0.27-1.98)$ CHA2DS2-VASC score, median (IQR) $6 (5-7)$ $6 (5-7)$ $6 (5-7)$ $12 \times 1$ $14$ No-frail20 $15$ $1$ $21$ $1$ Pre-frail42 $31$ $1.11 (0.50-2.50)$ $35$ $0.85 (0.26-2.79)$ Prailty $33$ $32$ $21 \times 10 (0.58-2.60)$ $35 \times 0.26 (0.42-3.98)^2$ Core, predian (IQR) $81$ $78$ $1$ $77$ $1$ No-frail20 $15$ $1$ <td< td=""><td>Perinheral artery disease</td><td>,0</td><td>,,,</td><td>1.11 (0.05 2.00)</td><td>52</td><td>0.11 (0.10 0.91)</td></td<>	Perinheral artery disease	,0	,,,	1.11 (0.05 2.00)	52	0.11 (0.10 0.91)
No $22$ $22$ $21$ $3$ $3$ $65$ $0.25$ Prior stroke or transient ischaemic attackNo $71$ $68$ $1$ $88$ $1$ Yes $29$ $32$ $0.97$ ( $0.56$ - $1.68$ ) $11$ $0.35$ ( $0.12$ - $1.07$ )Prior systemic embolismNo $95$ $92$ $1$ $89$ $1$ Yes $5$ $8$ $1.79$ ( $0.71-4.51$ ) $11$ $1.32$ ( $0.28-6.13$ )Prior bleeding event $73$ $63$ $0.98$ ( $0.56-1.71$ ) $68$ $1.02$ ( $0.42-2.47$ )Bleeding predisposition $48$ $46$ $1$ $65$ $1$ Yes $52$ $54$ $1.46$ ( $0.87-2.45$ ) $35$ $0.69$ ( $0.31-1.56$ )Liver disease $75$ $69$ $1$ $85$ $1$ No $72$ $75$ $1$ $70$ $1$ Yes $28$ $25$ $1.12$ ( $0.63-1.99$ ) $30$ $0.73$ ( $0.27-1.89$ )CHADDS2-VASC score, median (IQR) $6$ ( $5-7$ ) $6$ ( $5-7$ ) $1.02$ ( $0.58-1.80^{\circ}$ $5$ ( $5-7$ ) $0.97$ ( $0.40-2.39^{\circ}$ Prahty $7$ $1$ $22$ $11$ $0.89$ ( $0.70-1.12^{\circ}$ $5$ ( $3-8$ ) $0.56$ ( $0.42-0.99^{\circ}$ )Prior fail $20$ $15$ $1$ $21$ $1$ $1$ $1.90$ No-frail $20$ $15$ $1$ $21$ $1$ No $7$ $4-10$ $86(-11)$ $0.89$ ( $0.70-1.12^{\circ}$ $5(-8)$ $0.85$ ( $0.26-2.79$ )Prior fails $22$ $12$ $11$ $10.00$ $6(-$	No	30	29	1	37	1
Total       Total <th< td=""><td>Ves</td><td>68</td><td>71</td><td>1 42 (0 80-2 53)</td><td>63</td><td>0 65 (0 29-1 46)</td></th<>	Ves	68	71	1 42 (0 80-2 53)	63	0 65 (0 29-1 46)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Prior stroke or transient ischaemic attack	00	71	1.12 (0.00 2.00)	05	0.05 (0.25 1.10)
No12330.97 (0.56-1.68)110.035 (0.12-1.07)Prior systemic embolism95921891No95921891Yes581.79 (0.71-4.51)111.32 (0.22-6.13)Prior bleeding event73630.98 (0.56-1.71)68100 (0.42-2.47)Bleeding predisposition73630.98 (0.56-1.71)68100 (0.42-2.47)Bleeding predisposition73691851Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes28251.13 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes28251.12 (0.58-1.80)°5 (5-7)0.97 (0.40-2.39)°CH2DS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)°5 (5-7)0.97 (0.40-2.39)°CH2DS2-VASC score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12)°3 (3-4)0.64 (0.42-0.98)°CCL7 (4-10)8 (6-7)1.02 (0.58-1.30)°5 (5-7)0.97 (0.40-2.39)°Prailty921.11 (0.50-2.50)350.85 (0.26-2.79)No7 (4-10)8 (1-10)0.89 (0.70-1.12)°5 (3-8)0.65 (0.43-0.98)°No11111No11111 <td>No</td> <td>71</td> <td>68</td> <td>1</td> <td>88</td> <td>1</td>	No	71	68	1	88	1
The systemic embolismThe base (0.10 mod)The base (0.10 mod)The base (0.11 mod)No95921891Yes58 $1.79$ (0.71-4.51)11 $1.32$ (0.28-6.13)Prior bleeding event73630.98 (0.56-1.71)68 $1.02$ (0.42-2.47)Bleeding predisposition73630.98 (0.56-1.71)68 $1.02$ (0.42-2.47)Bleeding predisposition73691651Yes5254 $1.46$ (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes2531 $1.38$ (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes2825 $1.12$ (0.63-1.39)300.73 (0.27-1.98)CHA2D52-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80) <sup>6</sup> 5 (5-7)CHA2D52-VASc score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12) <sup>6</sup> 3 (3-4)Non-frail20151211Pre-frail4231 $1.11$ (0.50-2.50)350.65 (0.45-0.39)Pre-frail221.10 (0.58-2.60)231.18 (0.45-3.10)Pre-frail221.10 (0.59-2.39)451.40 (0.45-4.34)History of falls781771No81781771No81781	Ves	29	32	0.97 (0.56-1.68)	11	0 35 (0 12–1 07)
No95921891Yes581.79 (0.71-4.51)111.32 (0.28-6.13)Prior bleeding event73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition75691851No48461651Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701No72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHA2DS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)CCI7 (4-10)8 (6-11)0.89 (0.70-1.12)^c3 (3-4)0.64 (0.42-0.39)^cFrailty911110.50-2.50)350.55 (0.26-2.79)Frail20151211No1512111No187111No19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.92-1.2)^448 (41-54)0.80 (0.63-1.02)^6 </td <td>Prior systemic embolism</td> <td>23</td> <td>52</td> <td>0.57 (0.50 1.00)</td> <td>11</td> <td>0.55 (0.12 1.07)</td>	Prior systemic embolism	23	52	0.57 (0.50 1.00)	11	0.55 (0.12 1.07)
No581.79 (0.71-4.51)111.32 (0.28-6.13)Prior bleeding event73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition48461651Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CH2DS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)0.97 (0.40-2.39)^cHAS-BLED score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12)^c3 (3-4)0.64 (0.42-0.98)^cCCI7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailtyNo151211No38532.01 (0.58-4.39)451.40 (0.45-4.34)No81781771Yes19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^cGFRCKDEFERC (ml/min/1.73 m²), median (IQR)72 (5-30)28 (26-31)1	No	95	92	1	89	1
No27371321No27371321Yes73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition73630.98 (0.56-1.71)681.02 (0.42-2.47)No48461651Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHADS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)CCI7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cYrailty7120151211Non-frail201512111Pre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frailty921.00 (0.95-4.39)451.40 (0.45-4.34)History of falls7122311.88 (0.45-3.10)No817817711Yes19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m2), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1	Yes	5	8	1 79 (0 71-4 51)	11	1 32 (0 28-6 13)
No27371321Yes73630.98 (0.56-1.71)681.02 (0.42-2.47)Bleeding predisposition $$	Prior bleeding event	5	0	1.75 (0.71 1.51)	11	1.52 (0.20 0.15)
NoDDDD0101010101010100 <t< td=""><td>No</td><td>27</td><td>37</td><td>1</td><td>32</td><td>1</td></t<>	No	27	37	1	32	1
Iter is the second s	Yes	73	63	0.98 (0.56–1.71)	68	1 02 (0 42-2 47)
No48461651Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851No75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHA2DS2-VASC score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)0.97 (0.40-2.39)^cCHA2DS2-VASC score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12)^c3 (-4)0.66 (0.42-0.98)^cCCI7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailty7111Pre-frail20151211Pre-frail48532.01 (0.59-4.39)451.40 (0.45-4.34)History of falls71711No81781771Yes19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/n²), median (IQR)58 (38-71)58 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^ceGFR_CtD-EFter (ml/min/1.73 m²), median (IQR)58 (38-71)58 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^cAntiplatelet agent or NSAIDs use767918911.041 (0.12-1.43)Yes <td>Bleeding predisposition</td> <td>,5</td> <td>05</td> <td>0.50 (0.50 1.71)</td> <td>00</td> <td>1.02 (0.12 2.17)</td>	Bleeding predisposition	,5	05	0.50 (0.50 1.71)	00	1.02 (0.12 2.17)
No101014051Yes52541.46 (0.87-2.45)350.69 (0.31-1.56)Liver disease75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHAZDS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)0.97 (0.40-2.39)^cKAS-BLED score, median (IQR)3 (3-4)3 (3-4)3 (3-4)0.89 (0.70-1.12)^c3 (3-4)0.66 (0.42-0.98)^cCCI7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailty71111Pre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frail20151211Pre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frail20151211Pre-frail42311.11 (0.50-2.50)350.86 (0.26-2.79)Frail20151711Pre-frail221.00 (0.95-4.39)451.40 (0.45-4.34)History of falls1921.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^cOGFRC-CD-EPer (ml/min/1.73 m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^cOGFRC-	No	48	46	1	65	1
Liver diseaseIntroduct of LEDIntroduct of LEDIntroduct of LEDNo75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia $No$ 72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHA2DS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)0.97 (0.40-2.39)^cHAS-BLED score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12)^c3 (3-4)0.64 (0.42-0.98)^cCCI7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailty $No$ 711Pre-frail20151211Pre-frail20151211Pre-frail20151211Pre-frail20151211Pre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frailty921.00 (0.95-4.39)451.40 (0.45-4.34)History of falls921.00 (0.58-2.06)231.18 (0.45-3.10)Mo81781771Yes19221.00 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^ceGFR <sub>CKD-EFter</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)5	Yes	52	54	1 46 (0 87–2 45)	35	0 69 (0 31–1 56)
No75691851Yes25311.38 (0.77-2.46)150.39 (0.11-1.45)Dementia $No$ 72751701Yes28251.12 (0.63-1.99)300.73 (0.27-1.98)CHA2DS2-VASC score, median (IQR)6 (5-7)6 (5-7)1.02 (0.58-1.80)^c5 (5-7)0.97 (0.40-2.39)^cHAS-BLED score, median (IQR)3 (3-4)3 (3-4)0.89 (0.70-1.12)^c3 (3-4)0.69 (0.70-1.12)^c3 (3-4)0.69 (0.70-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailty7 (4-10)8 (6-11)0.89 (0.71-1.12)^c5 (3-8)0.65 (0.43-0.99)^cFrailtyNon-frail20151211Pre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frailty38532.01 (0.95-4.39)451.40 (0.45-4.34)History of falls7171No81781771Yes19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^ceGFR <sub>CKD-EPter</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66)1.07 (0.92-1.24)^d48 (41-54)0.80 (0.63-1.02)^dAntiplatelet agent or NSAIDs use76791891Yes24210.66 (0.34-1.28)110.41 (0.12-1.43)Total number of drugs, median (IQR)	Liver disease	52	51	1.10 (0.07 2.15)	33	0.05 (0.51 1.50)
No101013138 $(0.77-2.46)$ 150.39 $(0.11-1.45)$ Dementia2531 $1.38$ $(0.77-2.46)$ 15 $0.39$ $(0.11-1.45)$ Dementia72751701Yes2825 $1.12$ $(0.63-1.99)$ 30 $0.73$ $(0.27-1.98)$ CHA2DS2-VASc score, median (IQR)6 $(5-7)$ $6$ $(5-7)$ $1.02$ $(0.58-1.80)^c$ $5$ $(5-7)$ HAS-BLED score, median (IQR)3 $(3-4)$ $3$ $(3-4)$ $0.89$ $(0.70-1.12)^c$ $3$ $(3-4)$ $0.64$ $(0.42-0.98)^c$ CCI7 $(4-10)$ $8$ $(6-11)$ $0.89$ $(0.71-1.12)^c$ $5$ $(3-8)$ $0.65$ $(0.24-0.39)^c$ Frailty71201512111Pre-frail201512111Pre-frail4231 $1.111$ $(0.5-2.50)$ 35 $0.85$ $(0.26-2.79)$ Frailty3853 $2.01$ $(0.95-4.39)$ 45 $1.40$ $(0.45-4.34)$ History of falls7122 $1.10$ $(0.58-2.06)$ 23 $1.18$ $(0.45-3.10)$ BMI (kg/m²), median (IQR)27(25-30)28 $(26-31)$ $1.00$ $(0.92-1.24)^d$ $48$ $(41-54)$ $0.80$ $(0.63-1.02)^d$ Antiplatelet agent or NSAIDs use76791 $89$ 1 $1$ $0.41$ $(0.12-1.43)$ No76 <t< td=""><td>No</td><td>75</td><td>69</td><td>1</td><td>85</td><td>1</td></t<>	No	75	69	1	85	1
InterminationInterminationInterminationNo72751701Yes28251.12 $(0.63-1.99)$ 300.73 $(0.27-1.98)$ CHA2DS2-VASc score, median (IQR)6 (5-7)6 (5-7)1.02 $(0.58-1.80)^c$ 5 (5-7)0.97 $(0.40-2.39)^c$ HAS-BLED score, median (IQR)3 (3-4)3 (3-4)3 (3-4)0.89 $(0.70-1.12)^c$ 3 (3-4)0.64 $(0.42-0.98)^c$ CCI7 (4-10)8 (6-11)0.89 $(0.71-1.12)^c$ 5 (3-8)0.65 $(0.43-0.99)^c$ Frailty7120151211Non-frail20151211Pre-frail42311.11 $(0.50-2.50)$ 350.85 $(0.26-2.79)$ Frail38532.01 $(0.95-4.39)$ 451.40 $(0.45-4.34)$ History of falls781771No81781771Yes19221.10 $(0.58-2.06)$ 231.18 $(0.45-3.10)$ BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 $(0.94-1.07)^c$ 24 (22-28)0.86 $(0.76-0.97)^c$ GFR- <sub>CKD-EPler</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66)1.07 $(0.92-1.24)^d$ 48 $(41-54)$ 0.80 $(0.63-1.02)^d$ Antiplatelet agent or NSAIDs use76791891No76791891Yes24210.66 $(0.34-1.28)$ 110.41 $(0.12-1.43)$ Total number of drugs, median (IQR) <td>Yes</td> <td>25</td> <td>31</td> <td>1 38 (0 77–2 46)</td> <td>15</td> <td>0 39 (0 11–1 45)</td>	Yes	25	31	1 38 (0 77–2 46)	15	0 39 (0 11–1 45)
No72751701Yes2825 $1.12 (0.63-1.99)$ 30 $0.73 (0.27-1.98)$ CHA2DS2-VASc score, median (IQR)6 (5-7)6 (5-7) $1.02 (0.58-1.80)^c$ 5 (5-7) $0.97 (0.40-2.39)^c$ HAS-BLED score, median (IQR)3 (3-4)3 (3-4) $0.89 (0.70-1.12)^c$ 3 (3-4) $0.64 (0.42-0.98)^c$ CCI7 (4-10)8 (6-11) $0.89 (0.71-1.12)^c$ 5 (3-8) $0.65 (0.43-0.99)^c$ Frailty7 (4-10)8 (6-11) $0.89 (0.71-1.12)^c$ 5 (3-8) $0.65 (0.43-0.99)^c$ Frail20151211Pre-frail4231 $1.11 (0.50-2.50)$ 35 $0.85 (0.26-2.79)$ Frail38532.01 (0.95-4.39)45 $1.40 (0.45-4.34)$ History of falls81781771No81781771Yes1922 $1.10 (0.58-2.06)$ 23 $1.18 (0.45-3.10)$ BMI (kg/m²), median (IQR)27 (25-30)28 (26-31) $1.00 (0.94-1.07)^c$ 24 (22-28) $0.86 (0.76-0.97)^c$ eGFR <sub>CKD</sub> -EPIer (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66) $1.07 (0.92-1.24)^d$ 48 (41-54) $0.80 (0.63-1.02)^d$ Antiplatelet agent or NSAIDs useNo76791891No76791891Yes2421 $0.66 (0.34-1.28)$ 11 $0.41 (0.12-1.43)$ Total number of drugs, median (IQR)7(5-9)7 (5-11) $1.0$	Dementia	25	51	1.50 (0.77 2.10)	15	0.00 (0.11 1.10)
No12131316171717Yes2825 $1.12 (0.63-1.99)$ 30 $0.73 (0.27-1.98)$ CHA2DS2-VASc score, median (IQR)6 (5-7) $6 (5-7)$ $1.02 (0.58-1.80)^c$ 5 (5-7) $0.97 (0.40-2.39)^c$ HAS-BLED score, median (IQR)3 (3-4) $3 (3-4)$ $0.89 (0.70-1.12)^c$ $3 (3-4)$ $0.64 (0.42-0.98)^c$ CCI7 (4-10)8 (6-11) $0.89 (0.71-1.12)^c$ $5 (3-8)$ $0.65 (0.43-0.99)^c$ Frailty20151211Pre-frail4231 $1.11 (0.50-2.50)$ 35 $0.85 (0.26-2.79)$ Frail3853 $2.01 (0.95-4.39)$ 45 $1.40 (0.45-4.34)$ History of fallsNo81781771Yes1922 $1.10 (0.58-2.06)$ 23 $1.18 (0.45-3.10)$ BMI (kg/m²), median (IQR)27 (25-30)28 (26-31) $1.00 (0.94-1.07)^c$ 24 (22-28) $0.86 (0.76-0.97)^c$ eGFR <sub>CKD-EPter</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66) $1.07 (0.92-1.24)^d$ 48 (41-54) $0.80 (0.63-1.02)^d$ Antiplatelet agent or NSAIDs use76791891No76791891Yes2421 $0.66 (0.34-1.28)$ 11 $0.41 (0.12-1.43)$ Total number of drugs, median (IQR)7 (5-9)7 (5-11) $1.05 (0.97-1.13)^c$ 6 (4-8) $0.92 (0.81-1.05)^c$	No	72	75	1	70	1
CHA2DS2-VASc score, median (IQR)6 (5-7) $6$ (5-7) $1.02$ ( $0.58-1.80$ ) $5$ (5-7) $0.97$ ( $0.40-2.39$ )HAS-BLED score, median (IQR)3 (3-4)3 (3-4)3 (3-4) $0.89$ ( $0.70-1.12$ ) $5$ (3-8) $0.66$ ( $0.42-0.98$ )CCI7 (4-10)8 (6-11) $0.89$ ( $0.71-1.12$ ) $5$ (3-8) $0.65$ ( $0.43-0.99$ )Prailty7 (4-10)8 (6-11) $0.89$ ( $0.71-1.12$ ) $5$ (3-8) $0.65$ ( $0.43-0.99$ )Prailty7120151211Pre-frail4231 $1.11$ ( $0.50-2.50$ )35 $0.85$ ( $0.26-2.79$ )Frail38532.01 ( $0.95-4.39$ )45 $1.40$ ( $0.45-4.34$ )History of falls7122 $1.10$ ( $0.58-2.06$ )23 $1.18$ ( $0.45-3.10$ )BMI (kg/m²), median (IQR)27 (25-30)28 (26-31) $1.00$ ( $0.94-1.07$ )24 (22-28) $0.86$ ( $0.76-0.97$ )eGFR <sub>CKD-EPter</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66) $1.07$ ( $0.92-1.24$ ) $48$ ( $41-54$ ) $0.80$ ( $0.63-1.02$ )Antiplatelet agent or NSAIDs use76791891No76791891Yes2421 $0.66$ ( $0.34-1.28$ )11 $0.41$ ( $0.12-1.43$ )Total number of drugs, median (IQR)7 (5-9)7 (5-11) $1.05$ ( $0.97-1.13$ ) $6$ (4-8) $0.92$ ( $0.81-1.05$ )	Yes	28	25	1 12 (0 63–1 99)	30	0 73 (0 27–1 98)
HAS-BLED score, median (IQR)3 (3-4)3 (3-4) $3 (3-4)$ $3 (3-4)$ $3 (3-4)$ $3 (3-4)$ $3 (3-4)$ $0.69 (0.70-1.12)^c$ $3 (3-4)$ $0.64 (0.42-0.98)^c$ CCI7 (4-10)8 (6-11) $0.89 (0.71-1.12)^c$ 5 (3-8) $0.65 (0.43-0.99)^c$ FrailtyNon-frail20151211Pre-frail4231 $1.11 (0.50-2.50)$ 35 $0.85 (0.26-2.79)$ Frail38532.01 (0.95-4.39)45 $1.40 (0.45-4.34)$ History of fallsNo81781771Yes1922 $1.10 (0.58-2.06)$ 23 $1.18 (0.45-3.10)$ BMI (kg/m <sup>2</sup> ), median (IQR)27 (25-30)28 (26-31) $1.00 (0.94-1.07)^c$ 24 (22-28) $0.86 (0.76-0.97)^c$ eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)58 (38-71)58 (46-66) $1.07 (0.92-1.24)^d$ 48 (41-54) $0.80 (0.63-1.02)^d$ Antiplatelet agent or NSAIDs use76791891Yes2421 $0.66 (0.34-1.28)$ 11 $0.41 (0.12-1.43)$ Total number of drugs, median (IQR)7 (5-9)7 (5-11) $1.05 (0.97-1.13)^c$ 6 (4-8) $0.92 (0.81-1.05)^c$	CHA2DS2-VASc score median (IOR)	6 (5–7)	6 (5–7)	1 02 (0 58–1 80) <sup>c</sup>	5 (5-7)	0.97 (0.40-2.39)
Intersection $7 (4-10)$ $8 (6-1)$ $0.65 (0.1 - 1.12)^c$ $5 (6 + 1)$ $0.65 (0.1 - 0.13)^c$ FrailtyNon-frailPre-frailPre-frail42311.11 (0.50-2.50)350.85 (0.26-2.79)Frail38532.01 (0.95-4.39)451.40 (0.45-4.34)History of fallsNoNo81781Yes19221.10 (0.58-2.06)231.18 (0.45-3.10)BMI (kg/m²), median (IQR)27 (25-30)28 (26-31)1.00 (0.94-1.07)^c24 (22-28)0.86 (0.76-0.97)^ceGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m²), median (IQR)58 (38-71)58 (46-66)1.07 (0.92-1.24)^d48 (41-54)0.80 (0.63-1.02)^dAntiplatelet agent or NSAIDs useNo76791Yes24210.66 (0.34-1.28)110.41 (0.12-1.43)70 tal number of drugs, median (IQR)7 (5-9)7 (5-11)1.05 (0.97-1.13)^c6 (4-8)0.92 (0.81-1.05)^c	HAS-BLED score median (IQR)	3 (3-4)	3 (3-4)	0.89 (0.70–1.12) <sup>c</sup>	3 (3-4)	0.64 (0.42–0.98)
Gat $(1 \text{ for})$ $(0 \text{ for})$ </td <td>CCI</td> <td>7 (4–10)</td> <td>8 (6–11)</td> <td>0.89 (0.71–1.12)<sup>c</sup></td> <td>5 (3-8)</td> <td>0.65 (0.43-0.99)</td>	CCI	7 (4–10)	8 (6–11)	0.89 (0.71–1.12) <sup>c</sup>	5 (3-8)	0.65 (0.43-0.99)
Non-frail       20       15       1       21       1         Pre-frail       42       31       1.11 (0.50–2.50)       35       0.85 (0.26–2.79)         Frail       38       53       2.01 (0.95–4.39)       45       1.40 (0.45–4.34)         History of falls               No       81       78       1       77       1         Yes       19       22       1.10 (0.58–2.06)       23       1.18 (0.45–3.10)         BMI (kg/m <sup>2</sup> ), median (IQR)       27 (25–30)       28 (26–31)       1.00 (0.94–1.07) <sup>c</sup> 24 (22–28)       0.86 (0.76–0.97) <sup>c</sup> eGFR <sub>CKD-EPler</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)       58 (38–71)       58 (46–66)       1.07 (0.92–1.24) <sup>d</sup> 48 (41–54)       0.80 (0.63–1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use                No       76       79       1       89       1	Frailty	, (1 10)	0 (0 11)	0105 (017 1 1112)	5 (5 5)	0.00 (0.10 0.00)
Norm10101010111111Pre-frail4231 $1.11 (0.50-2.50)$ 35 $0.85 (0.26-2.79)$ Frail38532.01 (0.95-4.39)45 $1.40 (0.45-4.34)$ History of falls $38$ 532.01 (0.58-2.06)23 $1.18 (0.45-3.10)$ No81781771Yes1922 $1.10 (0.58-2.06)$ 23 $1.18 (0.45-3.10)$ BMI (kg/m <sup>2</sup> ), median (IQR)27 (25-30)28 (26-31) $1.00 (0.94-1.07)^c$ 24 (22-28) $0.86 (0.76-0.97)^c$ eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)58 (38-71)58 (46-66) $1.07 (0.92-1.24)^d$ 48 (41-54) $0.80 (0.63-1.02)^d$ Antiplatelet agent or NSAIDs use76791891Yes2421 $0.66 (0.34-1.28)$ 11 $0.41 (0.12-1.43)$ Total number of drugs, median (IQR)7 (5-9)7 (5-11) $1.05 (0.97-1.13)^c$ 6 (4-8) $0.92 (0.81-1.05)^c$	Non-frail	20	15	1	21	1
InternationInternationInternationInternationInternationInternationFrail38532.01 (0.95–4.39)451.40 (0.45–4.34)History of falls $No$ 81781771Yes19221.10 (0.58–2.06)231.18 (0.45–3.10)BMI (kg/m²), median (IQR)27 (25–30)28 (26–31)1.00 (0.94–1.07) <sup>c</sup> 24 (22–28)0.86 (0.76–0.97) <sup>c</sup> eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m²), median (IQR)58 (38–71)58 (46–66)1.07 (0.92–1.24) <sup>d</sup> 48 (41–54)0.80 (0.63–1.02) <sup>d</sup> Antiplatelet agent or NSAIDs useNo76791891Yes24210.66 (0.34–1.28)110.41 (0.12–1.43)Total number of drugs, median (IQR)7 (5–9)7 (5–11)1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)0.92 (0.81–1.05) <sup>c</sup>	Pre-frail	42	31	1 11 (0 50-2 50)	35	0.85 (0.26-2.79)
History of falls       81       78       1       77       1         Yes       19       22       1.10 (0.58–2.06)       23       1.18 (0.45–3.10)         BMI (kg/m²), median (IQR)       27 (25–30)       28 (26–31)       1.00 (0.94–1.07) <sup>c</sup> 24 (22–28)       0.86 (0.76–0.97) <sup>c</sup> eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m²), median (IQR)       58 (38–71)       58 (46–66)       1.07 (0.92–1.24) <sup>d</sup> 48 (41–54)       0.80 (0.63–1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use       76       79       1       89       1         Yes       24       21       0.66 (0.34–1.28)       11       0.41 (0.12–1.43)         Total number of drugs, median (IQR)       7 (5–9)       7 (5–11)       1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)       0.92 (0.81–1.05) <sup>c</sup>	Frail	38	53	2.01 (0.95-4.39)	45	1.40 (0.45-4.34)
No         81         78         1         77         1           Yes         19         22         1.10 (0.58–2.06)         23         1.18 (0.45–3.10)           BMI (kg/m <sup>2</sup> ), median (IQR)         27 (25–30)         28 (26–31)         1.00 (0.94–1.07) <sup>c</sup> 24 (22–28)         0.86 (0.76–0.97) <sup>c</sup> eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)         58 (38–71)         58 (46–66)         1.07 (0.92–1.24) <sup>d</sup> 48 (41–54)         0.80 (0.63–1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use         76         79         1         89         1           Yes         24         21         0.66 (0.34–1.28)         11         0.41 (0.12–1.43)           Total number of drugs, median (IQR)         7 (5–9)         7 (5–11)         1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)         0.92 (0.81–1.05) <sup>c</sup>	History of falls					
Yes     19     22     1.10 (0.58-2.06)     23     1.18 (0.45-3.10)       BMI (kg/m <sup>2</sup> ), median (IQR)     27 (25-30)     28 (26-31)     1.00 (0.94-1.07) <sup>c</sup> 24 (22-28)     0.86 (0.76-0.97) <sup>c</sup> eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)     58 (38-71)     58 (46-66)     1.07 (0.92-1.24) <sup>d</sup> 48 (41-54)     0.80 (0.63-1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use     76     79     1     89     1       Yes     24     21     0.66 (0.34-1.28)     11     0.41 (0.12-1.43)       Total number of drugs, median (IQR)     7 (5-9)     7 (5-11)     1.05 (0.97-1.13) <sup>c</sup> 6 (4-8)     0.92 (0.81-1.05) <sup>c</sup>	No	81	78	1	77	1
BMI (kg/m²), median (IQR)       27 (25-30)       28 (26-31)       1.00 (0.94-1.07) <sup>c</sup> 24 (22-28)       0.86 (0.76-0.97) <sup>c</sup> eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m²), median (IQR)       58 (38-71)       58 (46-66)       1.07 (0.92-1.24) <sup>d</sup> 48 (41-54)       0.80 (0.63-1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use       76       79       1       89       1         Yes       24       21       0.66 (0.34-1.28)       11       0.41 (0.12-1.43)         Total number of drugs, median (IQR)       7 (5-9)       7 (5-11)       1.05 (0.97-1.13) <sup>c</sup> 6 (4-8)       0.92 (0.81-1.05) <sup>c</sup>	Yes	19	22	1 10 (0 58-2 06)	23	1 18 (0 45-3 10)
eGFR <sub>CKD-EPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IQR)       58 (38-71)       58 (46-66)       1.07 (0.92-1.24) <sup>d</sup> 48 (41-54)       0.80 (0.63-1.02) <sup>d</sup> Antiplatelet agent or NSAIDs use       76       79       1       89       1         Yes       24       21       0.66 (0.34-1.28)       11       0.41 (0.12-1.43)         Total number of drugs, median (IQR)       7 (5-9)       7 (5-11)       1.05 (0.97-1.13) <sup>c</sup> 6 (4-8)       0.92 (0.81-1.05) <sup>c</sup>	BMI (kg/m <sup>2</sup> ) median (IOR)	27 (25–30)	28 (26–31)	1 00 (0 94–1 07) <sup>c</sup>	24 (22–28)	0.86 (0.76–0.97)
Antiplatelet agent or NSAIDs use       76       79       1       89       1         Yes       24       21       0.66 (0.34–1.28)       11       0.41 (0.12–1.43)         Total number of drugs, median (IQR)       7 (5–9)       7 (5–11)       1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)       0.92 (0.81–1.05) <sup>c</sup>	eGFR <sub>CKD-FPIcr</sub> (ml/min/1.73 m <sup>2</sup> ), median (IOR)	58 (38–71)	58 (46–66)	$1.07 (0.92 - 1.24)^{d}$	48 (41–54)	0.80 (0.63–1.02) <sup>d</sup>
No         76         79         1         89         1           Yes         24         21         0.66 (0.34–1.28)         11         0.41 (0.12–1.43)           Total number of drugs, median (IQR)         7 (5–9)         7 (5–11)         1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)         0.92 (0.81–1.05) <sup>c</sup>	Antiplatelet agent or NSAIDs use			(1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.		(
Yes         24         21         0.66 (0.34–1.28)         11         0.41 (0.12–1.43)           Total number of drugs, median (IQR)         7 (5–9)         7 (5–11)         1.05 (0.97–1.13) <sup>c</sup> 6 (4–8)         0.92 (0.81–1.05) <sup>c</sup>	No	76	79	1	89	1
Total number of drugs, median (IQR) 7 (5–9) 7 (5–11) $1.05 (0.97-1.13)^{\circ}$ 6 (4–8) $0.92 (0.81-1.05)^{\circ}$	Yes	24	21	0.66 (0.34–1.28)	11	- 0.41 (0.12-1.43)
	Total number of drugs, median (IQR)	7 (5–9)	7 (5–11)	1.05 (0.97–1.13) <sup>c</sup>	6 (4–8)	0.92 (0.81–1.05)

 $^{a}$ Categorical variables are described by their relative frequencies; continuous variables are described by their mean  $\pm$  SD if they are normally distributed or by their median [1st-3rd quartiles] if they are not.

<sup>b</sup>Odds ratio (OR) and 95% confidence intervals (95%CI) computed using univariable multinomial logistic regression with participants with appropriate dose as the reference.

<sup>c</sup>For a 1-unit increment.

<sup>d</sup>For a 10-ml/min/1.73m<sup>2</sup> increment.

 $\mathsf{eGFR}_{\mathsf{CKD}-\mathsf{EPIcr}}: \mathsf{estimated glomerular filtration rate using CKD-\mathsf{EPI creatinine}, \mathsf{NSAIDs}: non-steroidal anti-inflammatory agents.$ 



Figure 1: Dose status at baseline using various kidney function estimators (A) and Cockcroft–Gault according to drugs (B). C-G: creatinine clearance estimated by the Cockcroft–Gault equation; CKD-EPI and EKFC: GFR estimation using the Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium equations, based on serum creatinine (cr) and/or serum cystatin (cys).

found between participants having an appropriate dose using the  $\mbox{CrCl}_{C\cdot G}$  and eGFR equations.

# Dose status using indexed equations

Discrepancies in dose status defined by indexed versus deindexed eGFR varied by 3% for eGFR<sub>CKD-EPIcr</sub> to 9% for eGFR<sub>EKFCcr-cys</sub> (Supplementary Fig. 2). Discrepancies in dose status defined by indexed eGFR and  $CrCl_{C-G}$  varied by 9% for eGFR<sub>EKFCcr</sub> to 16% for eGFR<sub>CKD-EPIcys</sub> and eGFR<sub>EKFCcys</sub>. The association of endpoints with dose status using indexed eGFR was similar to de-indexed eGFR. However, underdose status was not associated with a lower risk of bleeding when using cystatin C-based eGFR<sub>CKD-EPIcys</sub> and eGFR<sub>EKFCcys</sub> (Supplementary Table 6).

## DISCUSSION

In this population of older adults with NVAF, DOAC dose adjustment was appropriate in the majority of patients, with discrepancies in dose status according to the considered drugs

Equation						
C-G	Dose status	Events/participants (%)	Unadjusted HR (95%CI)	HR using MSCM (95%CI)		
u-6	Underdos	26/52 (50)	1.31 (0.87-1.97)	1.22 (0.78-1.92)		
	Appropriate	74/154 (48)	1 (Ref)	1 (Ref)		A
	Overdosi	9/18 (50)	0.81 (0.36-1.87)	1.71 (0.68-4.27)	-	•
KD-EPicr						-
	Appropriate	87/142 / 47	1.43 (0.97-2.10)	1.22 (0.79-1.89) 1 (Pon		
	Overdosi	5/12 (40)	0.71 (0.27-1.91)	1.43 (0.37-5.49)	-	•
KD-EPicys						
	Underdose	21/44 (48)	1.10 (0.71-1.72)	0.91 (0.53-1.55)		
	Appropriate	73/153 (48)	1 (Ref)	1 (Ref)		
CKD-EPIcr-cy	s	1 10121 (04)	1.10 (0.36-2.10)	1.20 (0.00-2.40)		•
1799-1997-1997-1997-1997-1997-1997-1997	Underdos	29/56 (53)	1.22 (0.81-1.85)	1.01 (0.63-1.63)		
	Appropriate	70/150 (47)	1 (Ref)	1 (Ref)	•	
	Overdose	10/18 (54)	1.03 (0.47-2.23)	1.51 (0.64-3.56)	-	•
EKFCCF	Underdose	31/59 (54)	1.38 (0.92-2.07)	1.11 (0.70-1.76)		
	Appropriate	69/149 (46)	1 (Ref)	1 (Ref)		
	Overdose	12/22 (56)	0.77 (0.33-1.81)	1.76 (0.67-4.64)		
KFCcys						
	Underdose	26/52 (51)	1.15 (0.75-1.77)	1.02 (0.62-1.66)		
	Overdosi	12/22 (56)	1.01 (0.51-1.99)	1.07 (0.49-2.36)		
KFCcr-cys						
	Underdose	28/55 (51)	1.21 (0.79-1.83)	0.99 (0.60-1.61)	-	
	Appropriate	72/152 (48)	1 (Ref)	1 (Ref)		
	Overdosi	9/17 (52)	1.07 (0.49-2.32)	1.50 (0.64-3.52)	0.5 1	1.5 2 2.5 3 3.5
						HR (95%CI) using MSCM
			Here & March &	100		
uation G	Dose status	Events/participants (%)	unadjusted HR (95%CI)	HR using MSCM (95%CI)		
	Underdose	4/52 (8)	0.30 (0.07-1.28)	0.24 (0.05-1.12)	-	Р
	Appropriate	20/154 (13)	1 (Ref)	1 (Ref)		. в
	Overdose	1/18 (6)	0.41 (0.05-3.04)	0.78 (0.11-5.77)	•	
KD-EPIcr	Underste	0.70	0.00.00.00.0	0.70 /0.07 0.77	-	
	Appropriate	8/70 (11)	0.90 (0.37-2.16) 1 (Pan	0.78 (0.27-2.32) 1 (Path		
	Overdose	0/12 (0)	NA	NA		
D-EPicys						
	Underdose	2/44 (5)	0.63 (0.19-2.16)	0.60 (0.14-2.55)		
	Appropriate	19/153 (12)	1 (Ref)	1 (Ref)		
D-EPicr-cve	overdose	4/21 (15)	1.00 (0.56-4.92)	1.55 (0.47-5.11)		
ya	Underdose	5/56 (9)	0.60 (0.20-1.75)	0.50 (0.13-1.85)		
	Appropriate	19/150 (13)	1 (Ref)	1 (Ref)		•
	Overdose	1/18 (6)	0.48 (0.06-3.58)	0.34 (0.04-2.70)	•	
FCcr	10.00					
	Underdose	5/59 (9) 20/149 (12)	0.54 (0.19-1.59)	0.57 (0.14-2.27)	•	
	Overdose	0/17 (0)	NA	NA		
(FCcys						
	Underdose	6/52 (12)	0.92 (0.34-2.49)	0.71 (0.23-2.19)		
	Appropriate	17/150 (11)	1 (Ref)	1 (Ref)		
FCcr-cvs	Overdose	2/22 (9)	0.90 (0.22-3.77)	0.92 (0.18-4.63)		
	Underdose	5/55 (9)	0.59 (0.20-1.72)	0.50 (0.14-1.80)	-	
	Appropriate	20/152 (13)	1 (Ref)	1 (Ref)		
	Overdose	0/17 (0)	NA	NA		
					0 0.5	1 1.5 2 2.5 3 3.5
						LID IDENION
						HR (95%CI) using MSCM
ation	Dose status	Events/participants (%)	Unadjusted HR (95%CI)	HR using MSCM (95%Cl)		HR (95%CI) using MSCM
ation	Dose status	Events/participants (%)	Unadjusted HR (95%Cl)	HR using MSCM (95%CI)		HR (95%CI) using MSCM
ation	Dose status Underdose	Events/participants (%) 9/52 (17)	Unadjusted HR (95%Cl) 0.35 (0.15-0.82)	HR using MSCM (95%Cl)		HR (95%CI) using MSCM
ation	Dose status Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (20)	Unadjusted HR (95%Ct) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42.2 43)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18.1.57)		HR (95%CI) using MSCM
ation D-EPIcr	Dose status Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26)	Unadjusted HR (95%Cl) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42-2.43)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-1.57)		• C
ation D-EPIcr	Dose status Underdose Appropriate Overdose Underdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26) 14/70 (20)	Unadjusted HR (95%Cl) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42-2.43) 0.43 (0.22-0.86)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-1.57) 0.36 (0.17-0.78)	•••	- C
ation D-EPIcr	Dose status Underdose Appropriate Overdose Appropriate	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26) 14/70 (20) 42/142 (29)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42-2.43) 0.43 (0.22-0.86) 1 (Ref)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-1.57) 0.36 (0.17-0.76) 1 (Ref)		LIR (19/1/CI) using MSCM
D-EPIcr	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26) 14/70 (20) 42/142 (29) 5/12 (40)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1.(Ref) 1.01 (0.42-2.43) 0.43 (0.22-0.86) 1.(Ref) 1.89 (0.70-4.07)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-157) 0.36 (0.17-0.78) 1 (Ref) 0.65 (0.22-192)		L C
ation D-EPIcr D-EPIcys	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26) 14/70 (20) 42/142 (29) 5/12 (40)	Unadjusted HR (95%CI) 0.35 (0.15.0.82) 1.(Ref) 1.01 (0.42-2.43) 0.43 (0.22.0.86) 1.(Ref) 1.69 (0.70-4.07)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-1.57) 0.36 (0.17-0.78) 1 (Ref) 0.05 (0.22-1.92)		- C
ation D-EPIcr D-EPIcys	Dose status Underdose Appropriate Overdose Appropriate Overdose Underdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (26) 14/70 (20) 42/142 (29) 5/12 (40) 7/44 (17) 47/45 (29)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42-2.43) 0.43 (0.22-0.86) 1 (Ref) 1.69 (0.70-407) 0.47 (0.21-1.10) 1.072	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-1.57) 0.36 (0.17-0.78) 1 (Ref) 0.65 (0.22-192) 0.38 (0.15-0.92) 0.38 (0.15-0.92)	+ + +	C
ation D-EPIcr D-EPIcys	Dose status Underdose Appropriate Overdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 47/154 (30) 5/18 (20) 42/142 (20) 42/142 (20) 5/12 (40) 7/44 (17) 43/153 (20) 10/27 (20)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1.07 (0.42-2.43) 0.43 (0.22-0.86) 1.69 (0.70-4.07) 1.69 (0.70-4.07) 0.47 (0.21-1.10) 1.50 (0.76-3.06)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-157) 0.36 (0.17-0.78) 1 (Rei) 0.65 (0.22-192) 0.38 (0.15-0.98) 1 (Rei) 1 (0.042-53)	• • •	C
ation D-EPIcr D-EPIcys	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 147/0 (20) 518 (26) 147/0 (20) 518 (26) 77/44 (17) 43/153 (28) 1027 (36)	Unadjusted HR (85%CI) 0.35 (0.15-0.82) 1.640 1.01 (0.42-2.43) 0.43 (0.22-0.80) 1.69 (0.70-4.07) 0.47 (0.21-110) 1.69 (0.70-4.07) 0.47 (0.21-110) 1.62 (0.76-3.06)	HR using MSCM (95%Cl) 0.30 (0.12.0.76) 1 (Rei) 0.54 (0.18-1.57) 0.36 (0.17-0.78) (Rei) 0.65 (0.22-1.92) 0.38 (0.15-0.98) 1 (Rei) 1.06 (0.44-2.53)	• • •	C
D-EPIcr D-EPIcys D-EPIcr-cys	Dose status Underdose Appropriale Overdose Underdose Appropriale Overdose Underdose Appropriale Overdose	Events/part/cipants (%) 952 (17) 47/154 (20) 518 (26) 147/0 (20) 42/142 (29) 517 (40) 1517 (40) 1027 (38) 950 (15)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1 0.0 (0.42-4.3) 0.43 (0.22-0.86) 1 (Ref) 1 6.90 (0.70-4.07) 0.47 (0.21-110) 1 (Ref) 1 5.20 (0.76-3.06) 0.36 (0.16-0.82)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Ref) 0.54 (0.18-157) 0.36 (0.17-0.78) 1 (Ref) 0.85 (0.22-1.92) 0.38 (0.15-0.98) 1 (Ref) 1 06 (0.44-2.53) 0.29 (0.12-0.72)		L C
ation D-EPIcr D-EPIcys D-EPIcr-cys	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 516 (26) 14/70 (20) 42/142 (29) 5172 (40) 7,44 (17) 7,44 (17) 7,45 (15) 1027 (36) 9950 (15) 45/150 (30)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1.01 (0.42-2.43) 0.43 (0.22-0.86) 1.69 (0.70-4.07) 0.47 (0.21-10) 1.199 (0.70-4.07) 1.192 (0.76-3.06) 1.52 (0.76-3.06) 0.39 (0.16-0.82) 1 (Ref)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.34 (0.18-157) 1 (Rei) 0.36 (0.77-0.76) 1 (Rei) 0.36 (0.15-0.96) 1 (Rei) 1.06 (0.442-53) 0.29 (0.12-0.72) 1 (Rei)		C
ation D-EPIcr D-EPIcrs D-EPIcr-cys	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 9/52 (17) 4/1/54 (30) 5/18 (26) 4/2/142 (29) 5/12 (40) 7/144 (17) 4/3/153 (28) 1/0/27 (56) 4/3/150 (20) 7/18 (26)	Unadjusted HR (195%CQ) 0.55 (0.15.0.82) 10 (10.42.243) 0.43 (0.22.08) 1 (Fee) 1.69 (0.70.407) 0.47 (0.21.110) 1.69 (0.70.407) 1.52 (0.76.306) 0.30 (0.16.082) 1.69 (0.16.082) 1.42 (0.85.319)	HR using MSCM (95%Cl) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-1.57) 0.36 (0.17-0.78) 1 (Rei) 0.36 (0.15-0.98) 1 (Rei) 1 06 (0.44-2.53) 0.29 (0.12-0.23) 1 (Rei) 1.41 (0.43-4.68)		C
ation D-EPIcr D-EPIcys D-EPIcr-cys	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 1470 (20) 518 (26) 1470 (20) 518 (26) 1470 (20) 518 (26) 1470 (20) 7744 (17) 43153 (28) 1027 (26) 950 (15) 45150 (20) 7716 (38)	Unadjusted HR (85%CI) 0.35 (0.15-0.82) 1 (Ret) 1.01 (0.42.2.43) 0.43 (0.22-0.86) 1.89 (0.70.47) 0.47 (0.21-110) 1.89 (0.70.47) 1.52 (0.76.3.66) 0.36 (0.10.02) 1.16 (0.53.319) 1.42 (0.53.319)	HR using MSCM (95%Cl) 0.30 (0.12.0.76) 1 (Rei) 0.54 (0.18-1.57) 0.36 (0.17.0.78) 1 (Rei) 0.65 (0.22-1.92) 0.38 (0.15-0.98) 1 (Rei) 1 06 (0.44-2.53) 0.29 (0.12-0.72) 1.141 (0.43-4.66)	· · · · · · · · · · · · · · · · · · ·	L C
aation 	Dose status Underdose Appropriate Overdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose	Events/part/cipants (%) 952 (17) 47/154 (20) 5416 (20) 147/0 (20) 5412 (20) 5412 (20) 5412 (20) 5412 (20) 1027 (20) 950 (15) 45155 (20) 1027 (20) 7718 (20) 7115 (10) 1159 (10) 41159	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1 01 (0.42-2.43) 0 43 (0.22-0.86) 1 (Ref) 1 08 (0.70-4.07) 0 47 (0.21-110) 1 (Ref) 1 52 (0.76-3.06) 0 90 (0.16-0.82) 1 (Ref) 1 42 (0.63-3.19) 0 42 (0.19-0.80)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.36 (0.17-0.76) 1 (Rei) 0.36 (0.17-0.78) 1 (Rei) 0.36 (0.15-0.98) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 0.38 (0.15-0.72) 1 (Rei) 0.39 (0.12-0.72) 1 (Rei) 0.39 (0.13-0.74) 0.31 (0.13-0.74) 1 (Rei) 0.31 (0.13-0.74) 1 (Rei) 1 (Rei)		C
ation D-EPIcr D-EPIcys D-EPIcr-cys	Dose status Underdose Appropriate Overdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47154 (30) 518 (26) 14470 (20) 421142 (29) 5512 (40) 7744 (17) 43153 (28) 1027 (36) 956 (15) 45150 (30) 7718 (38) 1159 (18) 43149 (29) 81159 (18)	Unadjusted HR (195%CQ) 0.55 (0.15.0.82) 1 (Ref) 1 01 (0.42-243) 0.43 (0.22.08) 1 (Ref) 1 89 (0.70.407) 0.47 (0.21-1.10) 1 69 (0.70.407) 0.47 (0.21-1.10) 1 (Ref) 1 52 (0.76-306) 1 42 (0.85-3.19) 0.42 (0.19.0.89) 1 40 (0.46.2 PR) 1 10 (0.46.2 PR)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-157) 0.55 (0.22-192) 0.36 (0.17-0.76) 1 (Rei) 0.36 (0.15-0.96) 1 (Rei) 1 06 (0.44-253) 0.29 (0.12-0.72) 1 (Rei) 1.41 (0.43-460) 0.31 (0.13-0.74) 1 (Rei) 0.31 (0.13-0.74) 1 (Rei) 0.31 (0.23-177)		C
aation D-EPIcr D-EPIcr-cys PCcr	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 518 (28) 14/70 (20) 512 (40) 512 (40) 7/144 (17) 43/153 (28) 10/27 (36) 99/50 (15) 43/159 (16) 7/15 (38) 11/159 (16) 43/149 (29) 01/7 (34)	Unadjusted HR (85%CI) 0.55 (0.15-0.82) 1.64(0) 1.01 (0.42-243) 0.43 (0.22-0.80) 1.69 (0.70-4.07) 0.47 (0.21-110) 1.69 (0.70-4.07) 1.69 (0.70-4.07) 1.52 (0.76-3.06) 0.36 (0.16-0.82) 1.42 (0.53-319) 0.42 (0.19-0.89) 1.42 (0.53-319) 0.42 (0.19-0.89) 1.42 (0.62-3.19) 0.42 (0.19-0.89) 1.42 (0.62-3.19) 1.42 (0.19-0.89) 1.42 (0.19-0.89) 1.	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1. (Rei) 0.54 (0.18-157) 0.36 (0.17-0.78) 0.36 (0.15-0.98) 1. (Rei) 1.06 (0.44-253) 0.29 (0.12-0.72) 1. (Rei) 1.41 (0.43-4.68) 0.31 (0.13-0.74) 1. (Rei) 0.051 (0.23-1.67)		- C
aation D-EPIcr D-EPIcys D-EPIcr-cys :Ccr	Dose status Underdose Appropriate Overdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 1470 (20) 518 (26) 1470 (20) 518 (26) 1470 (20) 518 (26) 1470 (20) 7744 (17) 43153 (26) 1027 (26) 966 (15) 45150 (20) 7718 (38) 1159 (16) 43149 (29) 0177 (24)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ret) 1.07 (0.42.2.43) 0.43 (0.22-0.86) 1 (Ret) 1.69 (0.70-477) 0.47 (0.21-1.10) 1 (Ret) 1.52 (0.76-3.06) 0.36 (0.16-0.82) 1 (Ret) 1.42 (0.83-3.19) 0.42 (0.19-0.91) 1 (Ret) 1.10 (0.46.2.63) 0.37 (0.16-0.85)	HR using MSCM (95%CI) 0.30 (0.12.0.76) 1 (Rei) 0.54 (0.18-1.57) 0.36 (0.170.78) 0.38 (0.15-0.98) 1 (Rei) 1.06 (0.44.253) 0.29 (0.120.72) 1 (Rei) 1.41 (0.43-4.65) 0.31 (0.130.74) 1 (Rei) 0.31 (0.130.74) 1 (Rei) 0.31 (0.130.74) 1 (Rei) 0.32 (0.130.88)	· · · · · · · · · · · · · · · · · · ·	C
ation D-EPIcr D-EPIcr-cys Cccr	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Eventa/participants (%) 952 (17) 47154 (30) 518 (20) 1470 (20) 42142 (29) 512 (40) 7744 (17) 43155 (20) 1027 (20) 1027 (20) 1159 (10) 45150 (20) 7118 (20) 1159 (10) 45150 (20) 7159 (10) 45150 (20)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1 01 (0.42-2.43) 0 43 (0.22-0.86) 1 (Ref) 1 08 (0.70-4.07) 0 47 (0.21-110) 1 152 (0.76-3.06) 0 90 (0.16-0.82) 1 (Ref) 1 42 (0.63-3.19) 0 42 (0.19-0.86) 1 10 (0.46-2.43) 0 37 (0.16-0.86) 1 (Ref)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-157) 0.36 (0.17-0.78) 1 (Rei) 0.36 (0.15-0.98) 1 (Rei) 1 08 (0.42-53) 0.29 (0.12-0.72) 1 (Rei) 1.141 (0.43-4.60) 0.31 (0.13-0.74) 1 (Rei) 0.01 (0.23-167) 0.32 (0.13-0.80) 1 (Rei)	· · · · · · · · · · · · · · · · · · ·	R (#\$1/CI) using MSCM
ation D-EPIcr D-EPIcys D-EPIcr-cys Ccr	Dose status Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 14/70 (20) 42/142 (29) 512 (40) 77/44 (17) 43/153 (28) 10/27 (36) 94/50 (10) 77/18 (38) 43/169 (18) 43/169 (18) 43/169 (19) 617 (34) 852 (16) 8552 (16)	Unadjusted HR (95%CQ) 0.55 (0.15-0.82) 1040 101 (0.42-243) 0.43 (0.22-0.80) 1690 1690 (0.70-4.07) 1690 (0.16-0.82) 0.47 (0.21-1.10) 1690 152 (0.76-3.06) 0.50 (0.16-0.82) 1690 142 (0.85-3.19) 0.42 (0.19-0.89) 1690 100 (0.46-243) 1690 107 (0.46-243)	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-1.57) 0.36 (0.17-0.78) 1 (Rei) 0.36 (0.15-0.98) 1 (Rei) 1 0.60 (0.44-2.53) 0.29 (0.12-0.12) 1 (Rei) 1.41 (0.43-4.66) 0.31 (0.13-0.74) 1 (Rei) 0.61 (0.23-107) 1 (Rei) 0.32 (0.13-0.74) 1 (Re	· · · · · · · · · · · · · · · · · · ·	LI (1997) using MSCM
ation D-EPIcr D-EPIcrs D-EPIcr-cys CCr CCr	Does status Underdose Appropriate Overdose Underdose Appropriate Overdose Appropriate Overdose Appropriate Overdose Appropriate Overdose Appropriate Overdose Appropriate Overdose Appropriate Overdose Appropriate	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 147/0 (20) 518 (26) 147/0 (20) 512 (40) 77/44 (17) 43/153 (28) 1022 (38) 9950 (15) 44/5150 (20) 77/16 (38) 11559 (16) 43/149 (29) 64/17 (34) 8552 (16) 43/159 (20)	Unadjusted HR (85%CI) 0.35 (0.15.0.82) 1.67 (0.42.2.43) 0.43 (0.22.08) 1.89 (0.70.47) 0.47 (0.21.110) 1.89 (0.70.47) 0.47 (0.21.110) 1.52 (0.76.36) 0.36 (0.16.0.82) 1.42 (0.65.319) 0.42 (0.65.319) 0.42 (0.65.319) 0.42 (0.65.319) 1.42 (0.65.319) 0.42 (0.65.319) 0.47 (0.16.0.85) 1.10 (0.46.2.63) 1.10 (0.46.2.63) 1.10 (0.46.2.63)	HR using MSCM (95%CI) 0.30 (0.12.0.76) 1 (Rei) 0.54 (0.18-157) 0.36 (0.170.01 0.05 (0.22-192) 0.38 (0.150.98) 1 (Rei) 1.06 (0.44.253) 0.29 (0.12.0.72) 1.41 (0.43-463) 0.31 (0.13.0.74) 1 (Rei) 0.31 (0.13.0.74) 1 (Rei) 0.32 (0.13.0.80) 1 (Rei) 0.32 (0.13.0.82) 1 (Rei) 0.32 (0.13.0.80) 1 (Rei)	+ + + + + + + + + + + + + + + + + + + +	R (95%)(C) using MSCM
ation D-EPIcr D-EPIcys D-EPIcr-cys Ccr Ccrs	Dose status Underdose Appropriate Overdose Overdose Underdose Appropriate Overdose Overdose Underdose Appropriate Overdose	Events/participants (%) 952 (17) 47/154 (30) 518 (26) 147/0 (20) 518 (26) 147/0 (20) 518 (26) 147/0 (20) 518 (26) 147/0 (20) 77/8 (38) 45/150 (30) 77/8 (38) 45/150 (30) 77/8 (30) 65/150 (30) 77/2 (30) 85/2 (16) 45/150 (30) 77/2 (30) 85/150 (30) 77/2 (30) 85/150 (30)	Unadjusted HR (95%CI) 0.35 (0.15-0.82) 1 (Ref) 1.07 (0.42-2.43) 0.43 (0.22-0.86) 1 (Ref) 1.69 (0.70-4.07) 0.47 (0.21-1.10) 1 (Ref) 1.52 (0.76-3.06) 0.36 (0.16-0.82) 1.42 (0.63-3.19) 1.42 (0.63-3.19) 1.42 (0.63-3.19) 1.10 (0.46-2.63) 1.10 (0.46-2.63) 1.10 (0.46-2.43) 1.07 (0.16-0.82) 1.07 (0.46-2.43) 0.37 (0.16-0.82) 1.07 (0.46-2.43) 0.37 (0.16-0.82) 1.07 (0.46-2.43) 0.37 (0.16-0.82) 1.07 (0.46-2.43) 0.37 (0.16-0.82) 1.07 (0.46-2.43) 1.07 (0.46-2.43)	HR using MSCM (95%CI) 0.30 (0.12.0.76) 1 (Rei) 0.34 (0.16.157) 0.36 (0.17.0.76) 1 (Rei) 0.36 (0.150.02) 0.36 (0.150.02) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 1 (Rei) 0.29 (0.12.0.72) 1 (Rei) 0.29 (0.12.0.72) 1 (Rei) 0.31 (0.13.0.74) 1 (Rei) 0.31 (0.13.0.74) 1 (Rei) 0.32 (0.13.0.80) 1 (Rei) 0 (Rei) 1		RF (#51/Cf) using MSCM
Altion Al	Dose status Underdose Appropriate Overdose	Eventa/participants (%) 952 (17) 47154 (30) 518 (26) 14470 (29) 421142 (29) 512 (40) 7744 (17) 43153 (28) 1027 (36) 956 (15) 45150 (30) 7718 (38) 43149 (29) 3017 (34) 43149 (29) 3017 (34) 43150 (30) 772 (30)	Unadjusted HR (195%CQ) 0.55 (0.15.0.82) 1 (Fee) 1 01 (0.42-243) 0.43 (0.22.08) 1 69 (0.70.407) 1 69 (0.70.407) 1 69 (0.70.407) 1 69 (0.70.407) 1 69 (0.16.0.83) 1 69 (0.16.0.83) 1 69 (0.16.0.83) 1 50 (0.46.0.83) 1 50 (0.46.0.83) 1 50 (0.46.0.83) 1 50 (0.46.0.83) 1 50 (0.46.0.83) 1 50 (0.46.0.27) 1 50	HR using MSCM (95%CI) 0.30 (0.12-0.76) 1 (Rei) 0.54 (0.18-157) 0.55 (0.22-192) 0.36 (0.17-0.78) 1 (Rei) 0.36 (0.15-0.96) 1 (Rei) 1 106 (0.442-53) 0.29 (0.12-0.72) 1 (Rei) 1 141 (0.43-460) 0.31 (0.13-0.74) 1 (Rei) 0.31 (0.13-0.74) 1 (Rei) 0.32 (0.13-0.74)		LR (#\$1/C) using MSCM

Figure 2: Association between dose status and (A) mortality, (B) thromboembolism and (C) bleeding according to various kidney function estimators. Sums of events and sample size can slightly differ between estimators due to the multiple imputation process. C-G: creatinine clearance estimated by the Cockcroft–Gault equation; CKD-EPI and EKFC: GFR estimation using the Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium equations, based on serum creatinine (cr) and/or serum cystatin (cys).



Figure 3: Comparison of endpoint occurrence in patients with discrepancies in dose status according to the Cockcroft-Gault equation and eGFR. These participants are represented by the striped bars in Fig. 1A. P-values were obtained using univariable logistic regression models; CKD-EPI and EKFC: GFR estimation using the Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium equations, based on serum creatinine (cr) and/or serum cystatin (cys).

and kidney function estimators. Drug dose appropriateness was not associated with the occurrence of death and thromboembolism, no matter which kidney function estimator or underlying biomarker was used. The underdose group experienced fewer bleeding events with all the studied equations, but the overdose group did not experience a higher risk of bleeding.

Underdose status was more frequent than overdose status, as previously reported [5, 7–10]. The 69% of participants with an appropriate dose of DOACs was consistent with previous studies, which reported ranges from 63% to 87% [5, 7, 9, 10, 23, 31, 32]. However, dose appropriateness varied widely according to the considered drug. Previous studies found conflicting results about the most frequently underdosed and overdosed DOACs [7, 10, 23, 31, 32]. This discrepancy is likely to reflect various prescription practices and guidelines across countries, as well as differences in study population regarding kidney function. All dabigatran users were on appropriate drug doses at baseline. This could be explained by the small number of dabigatran users (n = 18), including only one patient with a medically indicated highest dose (i.e. 150 mg twice daily) and none with CKD stage 4 or 5.

Older age was the only factor significantly associated with the underdose status. Female sex, lower BMI, lower HAS-BLED score and lower CCI were significantly associated with overdose status. Older age, female sex and lower BMI have already been shown to be associated with an inappropriate dose of DOACS [5–10, 23]. Previous reports found conflicting results for the association between CCI and DOAC dose status [6, 9, 23]. Our results suggest that having a history of coronary artery disease was associated with a lower probability of being in the overdose group. Several studies found that cardiology followup was associated with an appropriate dose of DOACS [5, 33]. As patients with coronary artery disease are more likely to benefit from regular cardiology visits, this could explain this result.

Inappropriate dose status was not associated with mortality and thromboembolism. Whereas there was a lack of statistical power for the overdose group and the thromboembolism analysis with a high risk of type II error, this was unlikely the case for the mortality and bleeding analyses for the comparison of the appropriate and underdose groups. Previous studies that demonstrated increased mortality in patients with an inappropriate dose status included younger populations [5–8], which could explain the difference in results. It is possible that in a very old population with a high prevalence of multimorbidity and polypharmacy, the appropriateness of a single drug dose adjustment could be associated with bleeding or thromboembolism but not mortality. Underdose status was associated with a lower bleeding risk compared with the appropriate group, reconfirming former findings [7].

The discrepancies in drug dose status using the CrCl<sub>C-G</sub> and eGFR equations ranged from 7 to 13%, with higher discrepancies when using equations solely based on serum cystatin C. The discrepancy in dose status between the  $CrCl_{C-G}$  and  $eGFR_{CKD-EPIcr}$  (in ml/min) has been reported to range from 7 to 9% [12, 24, 34]. The low rate of discrepancies could explain why the association with endpoints did not differ according to the respective equations. Our results suggest that eGFR equations based on serum creatinine and/or cystatin C are not inferior to the  $CrCl_{C-G}$  in this context.

Our results differ from those obtained in dabigatran users showing a stronger association between dose status and bleeding when using the  $CrCl_{C-G}$  as compared with the eGFR<sub>CKD-EPIcr</sub> [12]. However, we were unable to perform a subgroup analysis

in dabigatran users and we cannot rule out that the results may differ according to the studied DOACs. We showed that being underdosed was associated with an increased risk of death and a decreased risk of bleeding in rivaroxaban users with several equations. In contrast, drug dose status was not associated with adverse events in apixaban users. This discrepancy in results between these two drugs could be explained by the lower rate of these events in apixaban users as compared with rivaroxaban users. Furthermore, renal clearance of apixaban is lower than that of rivaroxaban, which could partly explain why dose status was not associated with bleeding or mortality [4].

Patients with discrepancies in dose status are of great interest to study performances of kidney function estimators in drug dose adjustment. In a recent study, Chan et al. [17] reported a similar bleeding risk between vitamin K antagonist users and patients with discrepancies in dose status according to the  $CrCl_{C-G}$  and  $eGFR_{CKD-EPIcr}$ , with appropriate dose according to the eGFR<sub>CKD-EPIcr</sub>. The authors concluded that their results suggest that the CrCl<sub>C-G</sub> should be used as the gold standard for drug dose adjustment of DOACs, but no comparison was performed in patients with discrepancies in dose status with appropriate dose according to the  $CrCl_{C-G.}$  In our study, the association with endpoints did not significantly differ in patients with a discrepancy in dose status between the CrCl<sub>C-G</sub> and other equations, according to the equation for which the dose was appropriate. However, it should be noted that in patients for whom the dose was appropriate according to the CrCl<sub>C-G</sub>, the occurrence of endpoints was at least as high compared with patients with an appropriate dose according to other estimators, which could suggest that there is no disadvantage in using eGFR equations in these patients.

Using indexed equations (i.e. expressed in ml/min/1.73m<sup>2</sup>), the discrepancies between eGFR and  $CrCl_{C-G}$  were slightly higher (9–16%) than when using de-indexed equations. De-indexed eGFR has been proven to increase the correlation between the  $CrCl_{C-G}$  and eGFR and to improve performances of eGFR in drug dose adjustment, which could explain these results [35, 36]. If discrepancies between de-indexed and indexed equations were low (3–9%), it is likely that they occurred in patients with extremely low or high body weight. It would have been of great interest to do analyses stratified by body weight, but unfortunately the respective sample sizes were too small. For now, physicians should be advised to take BSA into account when using eGFR for drug dose adjustment, as recommended by current guidelines [13, 14].

Our study has several strengths. This is the first study assessing the impact of DOAC dose adjustment by kidney function using recent equations also including cystatin C. Given the paucity of clinical evidence on kidney function estimators for drug dose adjustment, which contrasts with the growing literature on equations to estimate GFR, our results could help physicians who daily face the issue of adapting drug dose to kidney function. The BIS detailed phenotyping including individual claims data allowed us to consider many confounders by computing marginal structural Cox models.

We must also acknowledge some limitations. First, the small sample size of the study did not allow us to study subgroups properly, such as patients with overdose status, edoxaban and dabigatran users, patients with extreme body weights and patients with discrepancies in dose status according to the studied equations. The prevalence of atrial fibrillation ranges from 12 to 18% in people >80 years of age in Europe [37], but we included 11% of the BIS participants. The low inclusion rate was mainly because the BIS was initiated in 2010, when the DOACs

started to be available in Germany but were not recommended as first-line therapy yet. Indeed, most participants were included in 2014 and later. Second, we did not have measured GFR to compare with the CrCl<sub>C-G</sub> and eGFR. Third, secondary endpoints were based on hospitalization diagnoses and we could not control their accuracy. Also, whereas thromboembolism is probably mainly treated in hospital, we may have missed less severe bleeding managed outside the hospital. Fourth, the definition of DOAC exposure could have led to biased results. We did not focus exclusively on new users, which could have excluded participants who had stopped taking DOACs due to adverse events before the inclusion. However, more than half of the participants at baseline were taking DOACs for <1 year. To further limit this bias, DOAC prescription duration was considered in our models. Dose status and DOAC use was only assessed at each follow-up visit, but medication could have been discontinued between visits. Also, our database did not include information on drug adherence. Fifth, as we focused on DOAC use in older adults with NVAF, our conclusions regarding drug dose adjustment for kidney function cannot necessarily be extrapolated to other drug classes in younger individuals.

## CONCLUSION

The association between adverse events and DOAC dose adjustment according to the  $CrCl_{C-G}$  and eGFR equations did not differ in older adults with NVAF. Our results suggest that eGFR equations based on serum creatinine and/or cystatin C are not inferior to the  $CrCl_{C-G}$  within this context. Future studies including a larger number of older participants, with discrepant dose status and focusing on other drug classes are important.

# SUPPLEMENTARY DATA

Supplementary data are available at ckj online.

# **FUNDING**

The BIS is funded by the KfH Foundation for Preventive Medicine and the DDnÄ Institut für Disease Management. C.V. received a post-doctoral stipend from Caen University Hospital.

# **AUTHORS' CONTRIBUTIONS**

C.V. was responsible for statistical analysis and writing the first draft of the manuscript. All authors were responsible for study concept and design, interpretation of data, significant contributions and final approval of the manuscript.

# DATA AVAILABILITY STATEMENT

The data underlying this article cannot be shared publicly to protect the privacy of individuals who participated in the study. The data will be shared upon reasonable request to the corresponding author.

# **CONFLICT OF INTEREST STATEMENT**

N.E. received fees from Bayer AG Leverkusen as a member of an editorial advisory board outside the submitted work. E.S. received a research grant from Bayer unrelated to the topic of the article and receives a stipend from the National Kidney Foundation. The other authors declare no conflicts of interests.

# REFERENCES

- Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1–88. https://doi.org/10.1093/ejcts/ezw313
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. https://doi. org/10.1159/000180580
- Kumar S, Lim E, Covic A et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 2019;74:2204–15. https://doi.org/10.1016/j.jacc.2019.08.1031
- Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association practical guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–93. https://doi.org/ 10.1093/eurheartj/ehy136
- Amarenco P, Haas S, Hess S et al. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J. Cardiovasc Pharmacother 2019;5:70–9. https://doi.org/10.1093/ehjcvp/pvy041
- Arbel R, Sergienko R, Hammerman A et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med 2019;132:847–55.e3. https://doi. org/10.1016/j.amjmed.2019.01.025
- Camm AJ, Cools F, Virdone S et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 2020;76:1425–36. https: //doi.org/10.1016/j.jacc.2020.07.045
- Steinberg BA, Shrader P, Thomas L et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016;68:2597–604. https://doi.org/10.1016/j.jacc.2016.09. 966
- Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation. Ann Pharmacother 2018;52:147–53. https://doi.org/10. 1177/1060028017728295
- Wattanaruengchai P, Nathisuwan S, Rattanavipanon W et al. Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. Br J Clin Pharmacol 2021;87:1390–400. https://doi.org/10.1111/bcp.14535
- Yao X, Shah ND, Sangaralingham LR et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:2779–90. https://doi.org/10.1016/j.jacc.2017.03.600
- 12. Simpson BH, Reith DM, Medlicott NJ et al. Choice of renal function estimator influences adverse outcomes with Dabigatran Etexilate in patients with atrial fibrillation. *TH Open* 2018;2:e420–7.
- **13**. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. London: European Medicines Agency, 2014.
- 14. US Food and Drug Administration. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing. Washington, DC: US Food and Drug Administration, 2020.

- Pottel H, Björk J, Rule AD et al. Cystatin C-based equation to estimate GFR without the inclusion of race and sex. N Engl J Med 2023;388:333–43. https://doi.org/10.1056/ NEJMoa2203769
- Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20–9. https://doi.org/10.1056/ NEJMoa1114248
- Chan Y-H, Chao T-F, Lee H-F et al. Different renal function equations and dosing of direct oral anticoagulants in atrial fibrillation. JACC Asia 2022;2:46–58. https://doi.org/10.1016/j. jacasi.2021.11.006
- 18. Rohla M, Pecen L, Cemin R et al. Reclassification, thromboembolic, and major bleeding outcomes using different estimates of renal function in anticoagulated patients with atrial fibrillation: insights from the PREFERin-AF and PREFER-in-AF prolongation registries. Circ Cardiovasc Qual Outcomes 2021;14:e006852. https://doi.org/10.1161/ CIRCOUTCOMES.120.006852
- Michels WM, Grootendorst DC, Verduijn M et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5:1003–9. https://doi.org/10.2215/CJN.06870909
- Xie Y, Bowe B, Mokdad AH et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018;94:567–81. https://doi.org/10. 1016/j.kint.2018.04.011
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 2021;16:217–21. https://doi.org/ 10.1177/1747493019897870
- Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 2017;73:759–70. https://doi.org/10.1007/ s00228-017-2225-3
- 23. Ruiz Ortiz M, Muñiz J, Raña Míguez P et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace 2018;20:1577–83. https://doi.org/10.1093/europace/eux316
- 24. Manzano-Fernández S, Andreu-Cayuelas JM, Marín F et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015;68:497–504.
- 25. Schaeffner ES, van der Giet M, Gaedeke J et al. The Berlin Initiative Study: the methodology of exploring kidney function in the elderly by combining a longitudinal and crosssectional approach. Eur J Epidemiol 2010;25:203–10. https:// doi.org/10.1007/s10654-010-9424-x

- Ebert N, Jakob O, Gaedeke J et al. Prevalence of reduced kidney function and albuminuria in older adults: the Berlin Initiative Study. Nephrol Dial Transplant 2017;32:997– 1005.
- Williamson T, Ravani P. Marginal structural models in clinical research: when and how to use them? Nephrol Dial Transplant 2017;32:ii84–90. https://doi.org/10.1093/ndt/ gfw341
- Grafféo N, Latouche A, Geskus RB et al. Modeling timevarying exposure using inverse probability of treatment weights. Biom J 2018;60:323–32. https://doi.org/10.1002/bimj. 201600223
- Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw 2011;45:1– 67.
- 30. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, 2004.
- 31. Khachatryan A, Doobaree IU, Spentzouris G et al. Direct oral anticoagulant (DOAC) dosing in patients with non-valvular atrial fibrillation (NVAF) in the United Kingdom: a retrospective cohort study using CPRD Gold Database. Adv Ther 2023;40:504–20. https://doi.org/10.1007/s12325-022-02368-y
- 32. Tzeis S, Savvari P, Skiadas I et al. Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation. J Thromb Thrombolysis 2021;51:81–8. https://doi.org/10.1007/s11239-020-02167-8
- Leiter MR, Packard KA, Qi Y et al. Improved dosing and administration of Rivaroxaban when prescribed by a cardiologist. Heart Int 2019;13:24–7. https://doi.org/10.17925/HI.2019. 13.1.24
- 34. Cemin R, Foco L, Zoccali C et al. Should we continue assessing glomerular filtration rate with the Cockroft–Gault formula in NOAC-treated patients? The magnitude of the problem. J Clin Med 2020;9:1893. https://doi.org/10.3390/jcm9061893
- 35. Schwartz JB. Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants. J Am Geriatr Soc 2016;64:1996–2002. https://doi.org/10.1111/jgs.14288
- 36. Chew-Harris JSC, Chin PKL, Florkowski CM et al. Removal of body surface area normalisation improves raw-measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese. Intern Med J 2015;45:766–73. https://doi.org/ 10.1111/imj.12791
- Wilke T, Groth A, Mueller S et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15:486–93. https://doi.org/10.1093/europace/ eus333

Received: 7.6.2023; Editorial decision: 25.7.2023

<sup>©</sup> The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com